Alprazolam intranasal - Questcor/Fabre Kramer
Alternative Names: Alprazolam intranasal - Questcor; PanistatLatest Information Update: 13 Oct 2005
At a glance
- Originator Questcor Pharmaceuticals
- Developer Fabre-Kramer Pharmaceuticals; Questcor Pharmaceuticals
- Class
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Panic disorder
Most Recent Events
- 13 Oct 2005 Discontinued - Preclinical for Panic disorder in USA (Intranasal)
- 05 Jul 2002 Fabre Kramer has licensed worldwide development and commercialisation rights from Questcor for intranasal alprazolam in the treatment of panic disorder
- 29 Jun 2002 Preclinical trials in Panic disorder in USA (Intranasal)